Anti-CD3 × Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers <i>In vitro</i> and in an Animal ModelUrsula Reusch, Lawrence G. Lum, James B. Davis et al.|Clinical Cancer Research|2006Cited by 106
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial resultsDavid A. Braun, David Sommerhalder, Marcus S. Noel et al.|Cell Reports Medicine|2026Cited by 1